Anti-human Tumor necrosis factor alpha (TNF-α) recombinant monoclonal antibodies
Adalimumab biosimilar antibodies comprise the variable region of Adalimumab and either the same constant region of Adalimumab or a different one with distinct effector functions (ADCC and ADCP).
Adalimumab which contains a human IgG1 constant region displays high effector functions; the other biosimilar features an IgA2 constant region that exhibits low effector functions. These two non-therapeutic antibodies can be used for the comparative study of the complex interactions induced by their Fc domains.
Key features
- Each lot is functionally tested and validated
- Choice of different isotypes for high/low effector functions
- The complete sequence of the antibody constructs has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
Adalimumab background
Adalimumab is a therapeutic, fully human IgG1 monoclonal antibody (mAb) that targets human tumor necrosis factor alpha (TNF-α). TNF-α is a pleiotropic cytokine involved in necrotic and apoptotic cell deaths, cellular differentiation, inflammation, and regulation of immune cell activity. It is mainly produced by activated monocytes, macrophages, and T cells, as transmembrane (tmTNF) or soluble (sTNF) trimeric proteins. Both forms bind homotrimeric transmembrane receptors, TNFR1 or TNFR2, leading either to cell death or proliferation and production of inflammatory cytokines, such as IL-6. Adalimumab blocks the interaction of both tmTNF and sTNF with TNFR1 and TNFR2. Adalimumab is used in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.
Read our product flyer on Clinically relevant monoclonal antibodies
